Charles Schwab’s Genelux GNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.3K Buy
25,023
+23
+0.1% +$65 ﹤0.01% 3415
2026
Q1
$60.5K Hold
25,000
﹤0.01% 3413
2025
Q4
$109K Hold
25,000
﹤0.01% 3394
2025
Q3
$105K Hold
25,000
﹤0.01% 3391
2025
Q2
$71.8K Hold
25,000
﹤0.01% 3429
2025
Q1
$67.5K Buy
+25,000
New +$93.8K ﹤0.01% 3376
2024
Q3
Sell
-90,303
Closed -$176K 3532
2024
Q2
$176K Sell
90,303
-62,206
-41% -$211K ﹤0.01% 3448
2024
Q1
$981K Buy
152,509
+2,905
+2% +$26.4K ﹤0.01% 2804
2023
Q4
$2.1M Buy
149,604
+1,995
+1% +$31.5K ﹤0.01% 2605
2023
Q3
$3.61M Buy
147,609
+128,909
+689% +$3.27M ﹤0.01% 2403
2023
Q2
$612K Buy
18,700
+3,524
+23% +$99.1K ﹤0.01% 2957
2023
Q1
$421K Buy
+15,176
New +$246K ﹤0.01% 3004

Other funds holding GNLX

Charles Schwab's GNLX Position: Q2 2026 in Review

Charles Schwab increased its Genelux (GNLX) stake by 0.09% in Q2 2026, buying an estimated $65 and bringing the position to 25,023 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

Charles Schwab first reported a position in GNLX in Q1 2023 and has held it in 12 quarters since. The position peaked at $3.61M in Q3 2023. 72 funds tracked by Wall St. Rank hold GNLX as of Q2 2026.

  • Charles Schwab held 25,023 shares of Genelux worth $75.3K as of Q2 2026.
  • Charles Schwab bought 23 Genelux shares in Q2 2026, an estimated $65.
  • Genelux made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3415 holding.
  • Charles Schwab first reported a position in Genelux in Q1 2023 and has held it in 12 quarters since.
  • Charles Schwab's Genelux position peaked at $3.61M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held Genelux as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.